EP PerMed - Research, Innovation and Technology Call (2026) - Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026)

In the frame of the European Partnership for Personalised Medicine, EP PerMed, (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), the French National Research Agency (ANR), in collaboration with 19 funding organisations, launches a joint transnational call for proposals as Research, Innovation and Technology Call on “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine, acronym: MultiPMData2026”. The available budget for this call is over 14.8 Mio€.

In the frame of the European Partnership for Personalised Medicine, EP PerMed, (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), the French National Research Agency (ANR), in collaboration with 19 funding organisations, launches a joint transnational call for proposals as Research, Innovation and Technology Call on “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine, acronym: MultiPMData2026”. The available budget for this call is over 14.8 Mio€.

The following countries (16) are participating in the call: Belgium, Czech Republic, Finland, France, Ireland, Israel, Italy, Latvia, Lithuania, Portugal, Romania, Slovak Republic, South Africa, Spain, Sweden and Turkiye. Three of the participating countries are represented by their specific regions (5): Flanders (Belgium), Wallonia (Belgium), Centro Region (Portugal), Andalusia (Spain), and Navarre (Spain).

The RITC2026 will fund innovation projects in human health that focus on multimodal data usage for PM approaches providing more efficient and personalised management of multimorbid patients, having at least two chronic diseases that require management.

Projects will address one or more of the following aspects:

• Detection or characterisation of co-morbidities in chronically ill patients;
• Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses;
• Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions;
• Decision support for disease intervention strategies (e.g., medication type and dosage);
• Tracking and managing multiple treatments (including drug combinations) to improve effectiveness or reduce adverse effects and potential harmful drug interactions;
• Adherence to long-term treatment regimens.

While clinical studies (exploratory/proof-of-concept/early stage clinical studies or sub-studies) can be funded in this call, larger clinical trials are out of scope.

Only transnational projects will be funded.

The transnational consortia have mandatorily to include a clinical partner as well as at least one SME (small and medium sized enterprise) or industry partner.

ANR will only fund the French partners of the selected projects. In agreement with ANR policy, funded researchers should respect the guidelines of the Nagoya protocol and consider open access publication of their results.

Erratum on 13/11/2025: 
Call Text – Pages 4, 24 and 27 : Change of a funder’s name: Israel Innovation Authority (ISERD) to National Technological Innovation Authority (IIA).
Call Text – Page 27 : Modification of the eligibility criteria in the table of Annex II for the funder « National Technological Innovation Authority, (IIA) ».
Guidelines for Applicants – Pages 17 et 36 : Change of a funder’s name: Israel Innovation Authority (ISERD) to National Technological Innovation Authority (IIA).